Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
First Game-Worn Supply Path Moves From Agreement Into Executed Sale and Photo-Match Verification MESA, AZ / ACCESS Newswire / September...
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation...
Initial Real-World User-Submitted Images Now in Internal Review, Advancing the Platform Beyond Public Cancer Imaging Archives MESA, AZ / ACCESS...
Subsidiaries Positioned to Supply and Authenticate Products for One of the World's Largest Sports Collectibles Platforms MESA, AZ / ACCESS...
Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September...
One AI Vision Core. Multiple Commercial Tracks Across Health, Agriculture, Foodservice, Consumer Wellness, Authentication, and Auctions. MESA, AZ / ACCESS...
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a...
Follow-Up to August 31 Announcement: First Cohort Process Is Now Open for Real-World Image Testing MESA, AZ / ACCESS Newswire...
Company Advances AI-Assisted Imaging Tools Designed to Help Users Track Possible Early Warning Signs and Visible Changes Over Time MESA,...
Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase MESA, AZ / ACCESS Newswire / August...
Company reviews methods designed to assist users in tracking visible skin changes over time with more accuracy. MESA, AZ /...
MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top...
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued...
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile...
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...
Company Maintains Active Development of Core AI Imaging Technology Alongside Diversified Revenue Platforms and Strategic Growth Considerations MESA, AZ /...
NANJING, China, Aug. 02, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code:...
From Mobile Apps and Enterprise Web Solutions to AI Authentication and Auction Software - MDCE Continues Building Revenue Streams While...